NCT03510104 2026-01-08
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Meryx, Inc.
Phase 1 Completed
Clinical Trials
3 trialsNCT04872478 2026-01-08
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx, Inc.
Phase 1 Recruiting
NCT04762199 2025-05-09
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Emory University
Phase 1 Recruiting